Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.
05:13am, Monday, 30'th Mar 2026
JPMorgan Chase and Co. lowered its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 28.5% during the undefined quarter, according to its most recent 13F filing with the Securitie
Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX
04:00am, Sunday, 15'th Mar 2026
Alkeon Capital Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 4.4% during the third quarter, according to the company in its most recent disclosure with the
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
03:07am, Saturday, 14'th Mar 2026
Avoro Capital Advisors LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 72.2% in the third quarter, according to its most recent 13F filing with the Securities an
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 04'th Mar 2026
RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst's board of directors granted s
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
01:58am, Friday, 27'th Feb 2026
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, Ma
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
03:08pm, Thursday, 26'th Feb 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
01:16pm, Thursday, 26'th Feb 2026
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.13 per share a year ago.
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
07:00am, Thursday, 26'th Feb 2026
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
11:01am, Thursday, 19'th Feb 2026
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSA Capital Partners LLP Acquires 78,827 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
04:16am, Wednesday, 18'th Feb 2026
GSA Capital Partners LLP lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 70.7% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 19
BioCryst to Present at Upcoming Investor Conference
07:00am, Tuesday, 17'th Feb 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Ca
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioede
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
07:01am, Thursday, 05'th Feb 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 05'th Feb 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 2
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Analysts
02:00am, Monday, 02'nd Feb 2026
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) has earned an average rating of "Moderate Buy" from the fourteen analysts that are currently covering the company, MarketBeat.com report
